sotatercept PAH
Selected indexed studies
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. (N Engl J Med, 2023) [PMID:36877098]
- A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. (Eur Respir J, 2025) [PMID:39978862]
- Sotatercept therapy for PAH. (Nat Rev Cardiol, 2021) [PMID:33888884]
_Worker-drafted node — pending editorial review._
Connections
sotatercept PAH is a side effect of
Sources
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. (2023) pubmed
- A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. (2025) pubmed
- Sotatercept therapy for PAH. (2021) pubmed
- Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial. (2023) pubmed
- Sotatercept in PAH: A promising pathway while awaiting long-term outcomes. (2025) pubmed
- Mechanisms and treatment of pulmonary arterial hypertension. (2025) pubmed
- Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. (2022) pubmed
- Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective. (2024) pubmed
- Sotatercept as add-on therapy for advanced PAH. (2025) pubmed
- PMID:39693471 (2024) pubmed